- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Brett Villagrand, Genentech
S
Brett Villagrand
Associate Director, Strategy, BioOncology, Genentech
BORN: Australia; has lived in four countries
CAN'T LIVE WITHOUT: Rugby
On brand success:
Herceptin revolutionized the way to treat HER2-positive breast cancer. I've been fortunate enough to work on that brand for the last three years—and to be here at Genentech at the right time. We've been fairly successful, with sales at around $1.3 billion. It's been a roller coaster ride to get there because the brand's more than doubled its growth over the last four or five years. Now we're facing competition for the first time. But despite the entry of a new competitor, we've been able to keep them to less than 5 percent of the market. Far from resting, we've instead put a number of things in place that will help us maintain our leadership role in that area.
Brett Villagrand
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
